These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
783 related articles for article (PubMed ID: 16186598)
21. [Clinical significance of WHO classification and MDS 2000 classification in myelodysplastic syndromes]. Akiba M; Matsuda A; Misumi M; Yagasaki F; Bessho M Rinsho Ketsueki; 2001 Dec; 42(12):1162-9. PubMed ID: 11828718 [TBL] [Abstract][Full Text] [Related]
22. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. Balduini CL; Guarnone R; Pecci A; Centenara E; Invernizzi R; Ascari E Haematologica; 1999 Jan; 84(1):12-6. PubMed ID: 10091387 [TBL] [Abstract][Full Text] [Related]
23. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. Breccia M; Latagliata R; Cannella L; Carmosino I; De Cuia R; Frustaci A; Stefanizzi C; Santopietro M; Alimena G Leuk Res; 2009 Mar; 33(3):391-4. PubMed ID: 18676015 [TBL] [Abstract][Full Text] [Related]
24. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Cermák J; Vítek A; Michalová K Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930 [TBL] [Abstract][Full Text] [Related]
25. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943 [TBL] [Abstract][Full Text] [Related]
26. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia. Hui CH; Horvath N; Lewis I; To LB; Szabo F Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457 [TBL] [Abstract][Full Text] [Related]
27. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification]. Wang XQ; Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053 [TBL] [Abstract][Full Text] [Related]
28. [Prediction of survival in myelodysplastic syndrome. Analysis of 2 scoring systems with prognostic value]. Sanz GF; Sanz MA; Vallespí T; Cañizo MC; García S; Torrabadella M; San Miguel JF; Irriguible D Sangre (Barc); 1989 Feb; 34(1):41-6. PubMed ID: 2711284 [TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System. Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445 [TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes according to FAB and WHO classification. Single center experience. Haus O; Kotlarek-Haus S; Potoczek S; Czarnecka M; Duszenko E; Makowska I; Mirowska N; Kuliczkowski K Neoplasma; 2006; 53(2):136-43. PubMed ID: 16575469 [TBL] [Abstract][Full Text] [Related]
32. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505 [TBL] [Abstract][Full Text] [Related]
33. Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Domingo-Claros A; Larriba I; Rozman M; Irriguible D; Vallespí T; Aventin A; Ayats R; Millá F; Solé F; Florensa L; Gallart M; Tuset E; Lopez C; Woessner S Haematologica; 2002 Feb; 87(2):148-53. PubMed ID: 11836165 [TBL] [Abstract][Full Text] [Related]
34. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Kao JM; McMillan A; Greenberg PL Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988 [TBL] [Abstract][Full Text] [Related]
35. [Study on prognostic factors in twenty-five patients with myelodysplastic syndrome]. Toyama T; Uno H; Yamashita K; Kubuki Y; Suzuki M; Maeda K; Matsuoka H; Tsubouchi H Gan To Kagaku Ryoho; 1995 Feb; 22(2):227-32. PubMed ID: 7857097 [TBL] [Abstract][Full Text] [Related]
36. A comparative review of classification systems in myelodysplastic syndromes (MDS). Bennett JM Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011 [TBL] [Abstract][Full Text] [Related]
37. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome]. Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301 [TBL] [Abstract][Full Text] [Related]
38. Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival. Breccia M; Latagliata R; Carmosino I; Gentilini F; D'Elia GM; Levi A; Natalino F; Frustaci A; De Cuia MR; Alimena G Acta Haematol; 2007; 117(4):221-5. PubMed ID: 17259693 [TBL] [Abstract][Full Text] [Related]
39. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Font P; Loscertales J; Benavente C; Bermejo A; Callejas M; Garcia-Alonso L; Garcia-Marcilla A; Gil S; Lopez-Rubio M; Martin E; Muñoz C; Ricard P; Soto C; Balsalobre P; Villegas A Ann Hematol; 2013 Jan; 92(1):19-24. PubMed ID: 22948274 [TBL] [Abstract][Full Text] [Related]
40. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes]. Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]